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Abstract: Traumatic brain injury (TBI) leads to many undesired problems and complications, 
including immediate and long-term seizures/epilepsy, changes in mood, behavioral, and 
personality problems, cognitive and motor deficits, movement disorders, and sleep problems. 
Clinicians involved in the treatment of patients with acute TBI need to be aware of a number 
of issues, including the incidence and prevalence of early seizures and post-traumatic epilepsy 
(PTE), comorbidities associated with seizures and anticonvulsant therapies, and factors that can 
contribute to their emergence. While strong scientific evidence for early seizure prevention in 
TBI is available for phenytoin (PHT), other antiepileptic medications, eg, levetiracetam (LEV), 
are also being utilized in clinical settings. The use of PHT has its drawbacks, including cogni-
tive side effects and effects on function recovery. Rates of recovery after TBI are expected to 
plateau after a certain period of time. Nevertheless, some patients continue to improve while 
others deteriorate without any clear contributing factors. Thus, one must ask, ‘Are there any 
actions that can be taken to decrease the chance of post-traumatic seizures and epilepsy while 
minimizing potential short- and long-term effects of anticonvulsants?’ While the answer is 
‘probably,’ more evidence is needed to replace PHT with LEV on a permanent basis. Some 
have proposed studies to address this issue, while others look toward different options, including 
other anticonvulsants (eg, perampanel or other AMPA antagonists), or less established treat-
ments (eg, ketamine). In this review, we focus on a comparison of the use of PHT versus LEV 
in the acute TBI setting and summarize the clinical aspects of seizure prevention in humans 
with appropriate, but general, references to the animal literature.
Keywords: traumatic brain injury, TBI, seizures, epilepsy, seizure prevention, cognition,   
EEG, antiepileptic drugs
Introduction
In about 6% of patients with epilepsy, seizures are thought to be the result of previous 
head trauma; frequently, seizures in these patients are difficult to control with standard 
antiepileptic drugs (AEDs).1 The presence of early and late seizures has significant 
effect on subsequent outcomes, including medication use, quality of life, employment, 
and psychosocial adjustment. In these patients, the original insult is frequently identi-
fied from the history, but the severity of the injury may be difficult to judge. Based on 
studies conducted over the last several decades, patients who have suffered moder-
ate or severe traumatic brain injury (TBI) are typically placed on an AED right after 
the initial trauma, usually phenytoin (PHT), but more recently also on levetiracetam 
(LEV), in order to alter the progression of epileptogenesis to late seizures and epilepsy. 
If seizures are not present in the first 7 days after trauma, the AED is weaned, with an 
expectation that seizures will not occur in the future. Since the concept of seizure and 
epilepsy prevention after TBI is well established, it is incumbent upon us to determine Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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not only which factors, when present or absent in the latent 
period (time between trauma and late seizures), are impor-
tant for initiating and completing the cascade of events that 
eventually lead to seizure occurrence, but also how we can 
modulate or abort this process so that seizures never occur. It 
is imperative to develop strategies that change the process of 
epileptogenesis while concurrently decreasing the chance of 
the development of unwanted comorbidities (eg, worsening 
of cognitive deficits related to TBI and AEDs). Finally, it is 
important to be mindful of the financial implications – PHT 
was found to be more cost effective than LEV in a setting 
of seizure prevention after TBI, but this gap may be disap-
pearing with the costs becoming similar in the recent years, 
and this calculation did not take into account the effects of 
these treatments on long-term costs.2 
In this review focusing on the comparison between PHT 
and LEV, we summarize the clinical aspects of seizure pre-
vention in humans, with appropriate but general references 
to animal literature, and provide brief discussion of potential 
new developments.
Epidemiology of early vs 
late post-traumatic epilepsy
The epidemiology of post-traumatic epilepsy (PTE) is well 
established. Early seizures are defined as seizures occurring 
in the first 7 days of trauma, while PTE is defined as seizures 
occurring after this period.3 The incidence of early seizures 
after TBI is reported to be between 2.6% and 16.3%, with 
the differences being dependent mainly on study design.3,4 
At least in univariate analysis, the presence of early seizures 
predisposes the development of late PTE; overall early sei-
zures are thought of as an epiphenomenon and a result of an 
acute injury, with their presence not necessarily equating with 
the development of late PTE.3,4 In fact, the pathophysiologic 
mechanisms leading to early post-traumatic seizures are not 
clearly understood, and multiple factors are thought to play a 
role, including interruption of the blood–brain barrier, pres-
ence of hemorrhage, and injury-related excitotoxicity.5–8
The reported incidence of late PTE is dependent, in 
part, on the study design. In a population-based cohort of 
2,747 patients with TBI, the risk of PTE after a severe TBI 
was 7.1% at 1 year and 11.5% at 5 years. After moderate 
brain injury, the risk of PTE was 0.7% at 1 year and 1.6% at 
5 years. The risk of PTE was not increased after mild head 
injury defined as head injury without skull fracture with either 
loss of consciousness or posttraumatic amnesia lasting less 
than 30 minutes.9 In the trial of PHT versus placebo for seizure 
prevention after TBI, 86% of patients who developed seizures 
did so within 2 years of the incident trauma.10,11 Finally, in a 
large population-based study, the risk of PTE was relatively 
small and non-significantly elevated after mild injury (1.5 after 
adjusting for all other factors) and increased after moderate 
(2.9 times) and severe (17.0 times) TBI.3 Salazar et al12 reported 
the overall occurrence of PTE in 53% of Vietnam veterans 
who had suffered from various penetrating head wounds and 
who required neurosurgical intervention. More than 90% of 
PTE presented within the first 10 years of trauma; occurrence 
of PTE significantly correlated with multiple risk factors, 
including brain volume loss, the presence of metal fragment, 
hematoma, and residual neurological deficits.12 These authors 
estimated the risk of developing epilepsy within the first year 
of penetrating head trauma to be 580 times higher than in a 
population not at risk. Finally, a recent cross-sectional study 
investigated PTE in a cohort of the veterans of the Afghanistan 
and Iraq conflicts to show age-adjusted prevalence of 6.1 per 
1,000, with odds of developing epilepsy related to previous 
TBI of 18.77 (95% confidence interval [CI] 9.21–38.23) when 
compared with veterans who did not suffer TBI.13 Thus, the 
picture painted by these epidemiological studies is that the 
more severe the injury the more likely the person with TBI 
is to develop PTE; that more than 80% of PTE starts within 
2 years of TBI; that presence of skull fracture, penetrating 
injury, and neurological deficits predispose to the development 
of PTE; and that age at the time of injury may be a factor in 
the development of PTE.
Seizure and epilepsy prevention 
after TBI
The idea behind the use of AEDs in the immediate post-injury 
period is based on the desire to prevent the development of 
late PTE as a long-term, and at times debilitating, comorbid-
ity, ie, finding a time window for an intervention that will 
stop the process of epileptogenesis.7 However, it needs to be 
recognized that besides seizures and PTE, TBI is frequently 
followed by various immediate and long-term deficits.7,14,15 
These include, among others, focal neurological deficits, cog-
nitive problems, changes in mood (eg, depression), movement 
disorders, sleep disorders, and behavioral problems. Some 
of these deficits may improve or resolve relatively quickly 
after the injury while some of them may worsen after initial 
improvement.16,17 Further, information on how treatment with 
AEDs in the acute phase influences long-term outcomes, 
including the development of PTE, is relatively sparse. Pro-
phylaxis against seizures is a part of standard therapy in the 
acute phase of moderate or severe TBI. As per guidelines 
from multiple organizations, including the Brain Trauma Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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Foundation and the American Academy of Neurology, the 
most commonly used prophylactic agent is PHT, which is 
typically administered for the first 7 days after TBI.18,19 But, 
while prophylaxis with PHT decreases the incidence of early 
posttraumatic seizures from 14.2% to 3.6% when compared 
with placebo, this treatment has not been shown to decrease 
the risk of late posttraumatic seizures and epilepsy.1,11
PHT has numerous side effects and drug interactions and 
exhibits complex nonlinear pharmacokinetics that necessitate 
therapeutic drug monitoring; its steady state concentrations 
are often not achievable within the first 7 days of therapy. 
Further, maintaining therapeutic levels of PHT is challenging 
in patients with TBI because the levels are affected by mul-
tiple factors frequently present in TBI patients, including 
decreased protein binding, variable gastrointestinal absorp-
tion, and increased drug clearance.20 Further, while PHT 
reduces seizures, concerns have been raised that it may also 
adversely affect cognitive recovery, at least in some forms 
of brain injury. A recent study investigated the outcomes 
of patients treated with PHT for seizure prophylaxis after 
TBI compared with matched patients who, based on clini-
cal judgment, had not received PHT prophylaxis.20 While 
no differences were observed in the incidence of seizures 
between groups, patients treated with PHT showed worse 
outcomes, including Glasgow Outcomes Scale and modified 
Ranking Scale (both P0.05). Multiple caveats to this study 
need to be considered, including small sample size, lack of 
randomization, and the choice of treatment versus no treat-
ment based on personal preferences of the providers rather 
than predetermined schemes.20
An alternative to PHT may be LEV, an agent recently 
added to the seizure-prevention armamentarium.21–25 The 
availability of this AED is especially relevant for critically 
ill patients with TBI because of the ease of administration, 
low rate of adverse events, and potential for improved 
outcomes.19,20,24 A recently reported small-scale, single-
blinded randomized trial suggests the use of LEV rather than 
PHT in acute TBI may be associated with better 6-month 
cognitive outcomes.24,26 While promising, these preliminary 
single-blinded data are not sufficient to warrant a change 
in clinical practice. More studies are needed to determine 
its long-term impact after injury. To date, no prospective, 
double-blind randomized controlled trials (RCTs) have 
been conducted to compare the effects of LEV versus PHT 
on neurocognitive and seizure outcomes among individuals 
with moderate or severe TBI.27,28
Several ‘older’ AEDs have been evaluated for the treat-
ment of early post-traumatic seizures with a goal of targeting 
the development of late PTE. These include PHT, valproate 
(VPA), and carbamazepine (CBZ).18,24 The available data 
on PHT, VPA, and CBZ were reviewed in a recent ‘practice 
parameter’ and are discussed here only briefly.18 For PHT, 
evidence from pooled studies indicates a significantly lower 
risk of early post-traumatic seizures in patients who receive 
PHT for seizure prophylaxis when compared with placebo 
(relative risk 0.37) and no reduction in late post-traumatic sei-
zures (relative risk 1.05). Oral (via feeding tube) CBZ, given 
immediately after TBI and continued for 18–24 months, was 
used for seizure prophylaxis in one quasi-randomized study 
in which outcomes were compared with a placebo group.29 
Patients treated with CBZ showed a significantly lower 
probability of early and late post-traumatic seizures, but the 
results of this study are confounded by the fact that patients 
were treated initially with intravenous PHT until they were 
able to receive oral CBZ. Finally, one study evaluated VPA 
for seizure prevention after TBI to show similar incidences of 
seizures in patients randomized to 1 week of PHT, 1 month 
of VPA, or 6 months of VPA (P=0.19) and a trend toward 
higher mortality with VPA (P=0.07); the effects of both 
AEDs on neuropsychological health were similar.30,31 Based 
on these results the use of VPA for seizure prevention cannot 
be recommended. Overall, this is surprising because VPA 
has been shown to be neuroprotective in several models of 
acute central nervous system injury (for review, see Chen 
et al32). Thus, the available studies provide level 1 evidence 
for the short-term use of PHT for seizure prevention in the 
setting of acute brain injury, while the use of VPA and CBZ 
in this setting is questionable. Currently, there is no class I 
evidence that the ‘older’ AEDs should be used for long-term 
prevention of PTE.18
The results of the previous studies put into perspective the 
proposed use of LEV in the setting of acute TBI. In animal 
studies, LEV has been shown to have several mechanisms 
of action, including modulation of neuropeptide Y receptors 
and neuronal Ca++ channels, threshold elevation for L-type 
Ca++ channel neuronal currents, modulation of neurotrans-
mitter release via binding to the synaptic vesicle protein 
2A (inhibition of Ca++ release from intracellular stores), 
and opposition of the negative modulation of gamma-
aminobutyric acid (GABA)- and glycine-gated currents.21,33 
These mechanisms of action could explain the unique 
antiepileptogenic activity of LEV, including neuroprotec-
tion, seizure prevention, and improved cognitive outcomes 
of LEV use in animal models of brain injury, and support 
its use for seizure prevention in moderate and severe TBI. 
To offer more detail, LEV has recently been shown to be Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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neuroprotective in a rodent model of controlled cortical 
impact (CCI) and subarachnoid hemorrhage (effect that has 
not been observed with PHT); administration of LEV but 
not PHT improved functional outcomes.34 Another rodent 
study showed that 20 days of LEV treatment following CCI, 
when compared with placebo, promoted neuronal sparing, 
decreased the volume of injury, and reduced release of pro-
inflammatory interleukin (IL)-1β.35 Finally, LEV alone or in 
combination with diazepam decreased seizure-related hip-
pocampal neurodegeneration.36 Next is the issue of seizure 
prevention – the process of epileptogenesis (transformation 
of normal brain tissue into one capable of spontaneously 
generating seizures) can be prevented or aborted by LEV.37 
While it is recognized that LEV is not antiepileptogenic 
in all animal models, recent studies have shown that LEV 
aborts hyperexcitability in hippocampal neurons after status 
epilepticus,38 and that it exerts antiepileptogenic effects in 
spontaneously epileptic rats.39,40 Relevant to the discussion is 
the effect of LEV on cognition – rodents administered LEV 
beginning 1 day after CCI for 20 days showed improved 
motor and cognitive functions, including balance (beam 
walking), spatial learning and memory (maze navigation), 
and exploration.35
In the setting of TBI, some of the issues related to the use 
of AEDs revolve around the potential effects of these medica-
tions on EEG. This is because a growing body of evidence 
supports the notion that interictal epileptiform discharges 
(IEDs) and/or seizures result in long-term cognitive deficits. 
In fact, IEDs have been shown not only to affect cognitive 
performance, including alertness and speed of processing, 
at the moment of their occurrence41,42 but also to contribute 
to negative long-term cognitive outcomes such as decreased 
educational achievement.41–43 The negative effect of IEDs on 
cognition may be comparable to the effects of brief seizures.42 
There is also evidence that AEDs such as LEV may positively 
affect the EEG by suppressing IEDs44,45 and by improving the 
overall background of the EEG; these effects are not observed 
with PHT.46 In addition to IEDs, the other common EEG 
abnormalities observed in TBI are seizures.12,47,48 Because 
of the abundance of EEG abnormalities, it can be difficult to 
separate the short- and long-term effects of the injury alone 
from the associated seizures. Animal studies indicate that 
brain trauma causes global, in addition to focal, abnormali-
ties, and that these abnormalities are most pronounced in the 
most vulnerable areas – ie, hippocampus.49 Further, animal 
model research has documented the relationship between TBI 
and seizures50–52 and the positive impact of seizure medica-
tion treatments on improving neurobehavioral outcomes in 
TBI.35,53 Recently, human studies have shown that seizures in 
patients with TBI disproportionately contribute to hippocam-
pal atrophy,54 that seizures cause increases in intracranial 
pressure and increased lactate/pyruvate ratio, both of which 
have deleterious effects on post-TBI recovery,55,56 and that 
patients with seizures related to any type of brain injury, 
when compared with matched patients without injury, have 
poorer outcomes and higher mortality.57–60 Thus, there is little 
doubt that seizures and/or IEDs have a negative influence on 
recovery after TBI.
The next issue that requires consideration is cognitive per-
formance. It is well recognized that most AEDs have negative 
effects on cognition. The archetypical AED for these effects 
is topiramate, which has been shown to negatively affect 
cognitive performance in healthy subjects61–64 and in patients 
with epilepsy.65–68 The effects of PHT and LEV on cogni-
tion are not as pronounced and are likely different.24,25,69–74 
PHT has been noted to have significant long-term effects 
on cognition,69 including negative effects on concentration, 
memory, visuo-motor functions and mental speed; these 
effects may be dose related.75–77 Some studies have shown 
detrimental effects of PHT on cognitive performance when 
compared with other AEDs (eg, carbamazepine75,77,78), with 
these negative effects improving after PHT discontinuation.79 
On the other hand, LEV as a member of the pyrrolidine class 
of drugs, may improve cognition via enhancing higher inte-
grative mechanisms of the brain.80,81 In fact, LEV has been 
shown to improve a range of cognitive abilities, including 
visual short-term memory,82 working memory,83 motor 
functions,83 psychomotor speed and concentration,72,84 and 
fluid intelligence.85 Comparative data are scarce – while one 
small comparative study showed no difference in cognitive 
outcomes in patients with epilepsy treated with LEV versus 
PHT, the authors recognized the lack of power to detect 
such a difference (n=10; participants taking concurrently 
various AEDs including PHT, CBZ, and/or VPA).86 To 
date, systematic direct comparisons in patients with epilepsy 
have not been performed, but some studies have indicated 
improvements in cognition when patients were either tran-
sitioned to or treated with LEV monotherapy.44,46 Similar 
improvements in cognitive performance of patients with 
epilepsy while treated with PHT have not been observed or 
reported. Finally, individuals with existing cognitive weak-
nesses (as in TBI) may benefit most from LEV and, in fact, 
a blinded study showed that recent memory improved most 
in patients with poor baseline scores.87 In contrast to the rela-
tive paucity of epilepsy data, a recent study of patients with 
brain tumors after resection showed that the neurocognitive Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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performance of patients treated with LEV was equal to or 
better than that of matched patients not treated with any AEDs 
and better than the performance of patients treated with PHT 
or VPA; in contrast to treatment with PHT, treatments with 
LEV or VPA were not associated with additional cognitive 
deficits.88 Another study in an animal model of Alzheimer’s 
disease showed that treatment with LEV improved cogni-
tive performance via reduction of epileptiform discharges 
and reversal of hippocampal remodeling, behavioral abnor-
malities, synaptic dysfunction, and deficits in learning and 
memory.89 In addition to the effects described above, nega-
tive effects on EEG and cognitive performance have been 
observed in patients treated with PHT, especially at high 
doses and levels.90,91
Based on a single RCT, PHT has been shown to have a 
negative effect on cognitive outcomes in patients with TBI.69 
A recent study in subarachnoid hemorrhage showed that these 
effects may be dependent on the dose and treatment duration 
with PHT.73 These findings have led some to question the 
use of PHT in the setting of TBI.92 Newer AEDs, specifically 
LEV, may be better tolerated and have less adverse impact on 
the plasticity of recovery. Studies have shown that patients 
with various etiologies of brain injury, including TBI, expe-
rience better outcomes on a variety of measures (adverse 
effects, Modified Rankin Scale, Glasgow Outcomes Scale) 
when treated with LEV compared with PHT.24,25,93,94 To that 
end, one small retrospective non-randomized study in TBI 
evaluated cognitive performance and showed a trend toward 
improved outcomes among patients treated with LEV versus 
PHT (P=0.08).25 Finally, a single-blinded RCT has shown 
better Glasgow Outcome Scale and modified Rankin Scale 
outcomes in patients with moderate or severe TBI who were 
treated with LEV versus PHT.24
Evidence for seizures after brain 
injury and the effects of PHT vs LEV 
The likelihood of early seizures is related to the severity 
of brain injury.14 Further, as indicated above, there is some 
evidence that early seizures may translate into the devel-
opment of long-term epilepsy,95,96 though the data from 
population-based studies are not entirely in support of this 
notion.3,9 The factors that lead to the establishment of the 
long-term epileptic state are not fully understood, but there 
is considerable evidence to suggest that seizures in the acute 
period may drive changes that will result in the development 
of PTE. Early use of AEDs may prevent these changes from 
occurring, reverse the process of early epileptogenesis related 
to injury, and prevent chronic epilepsy.38,97,98
As mentioned previously, because of the short-term risk 
of seizures and long-term risks of epilepsy, patients with TBI 
are typically treated with AEDs for 7 days.99–101 The most fre-
quently used AED in this setting is PHT.1,11,18 However, PHT 
was also found to be associated with substantial liver toxicity, 
hypotension, hematologic abnormalities, drug interactions, 
and sedation, all of which are problematic in critically ill 
patients.24,94 Finally, as indicated above, studies suggest 
that the use of PHT in this setting is associated with adverse 
cognitive effects, negative effects on post-TBI recovery,24,25,69 
and even negative effects on brain anatomy.102
The incidence of acute post-TBI seizures depends on 
whether seizures are reported based on clinical (~2%) or 
continuous EEG (cEEG) (~22%) criteria.24,26,59,60,103 Recently, 
cEEG monitoring has been used to determine the incidence 
of early seizures in critically ill patients. In TBI studies that 
included cEEG, the incidence of early seizures was found to 
range from 16% to 22%, with the vast majority of seizures 
being non-convulsive (52%–100%); approximately 95% of 
the identified seizures occurred within 72 hours of trauma. 
Further, it has been shown that the use of cEEG leads to 
treatment changes in more than 50% of the monitored 
patients.104 These findings support the empiric use of AEDs 
and of the cEEG in the critical care setting.60,105–107 Finally, 
data from a recent randomized and blinded study support 
the notion that cEEG performed in the first 72 hours after 
TBI contributes to outcome prediction,26 with alpha vari-
ability being the most important predictive factor.108 Thus, 
suppressing or eliminating IEDs and seizures should result 
in improved cognitive performance, while knowledge of the 
cEEG characteristics can contribute to the overall long-term 
prediction of outcomes.
Patients with moderate or severe TBI admitted to 
neuroscience intensive care units are at increased risk for 
seizures due to their underlying neurological injury.3,9 
Early-onset seizures in patients with TBI greatly increase 
the incidence of subsequent seizures/epilepsy and the 
chance of secondary harm, including increased intracranial 
pressure, hypoxia, physical injury, and mortality.58,96,99 Any 
of these complications may adversely affect the cognitive 
and neurological status of patients with TBI, and worsen 
their clinical outcomes. Further, the presence of seizures 
or status epilepticus in patients with TBI, similar to other 
acute neurological insults such as stroke, is associated with 
increased mortality.58,60 Thus, seizure prevention is critical 
for the long-term outcomes of patients with brain injury, and 
cEEG may be a valuable biomarker of initial epileptogenicity 
and for long-term outcomes.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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Thus, to summarize, while there is no level 1 evidence 
that LEV may be equivalent to or better than PHT when 
used for seizure prevention in patients with TBI, there is 
a substantial body of evidence that the use of LEV should 
be considered in this setting, and further investigations 
are needed. Finally, prophylaxis of late PTE is neither 
indicated nor recommended. The data from observational 
studies and RCTs provide no evidence to support such 
use of AEDs.
Future directions
Clinical post-TBI recovery occurs over periods of months 
and years, and so does the process of epileptogenesis. 
In fact, epileptogenesis may progress in spite of clinical 
improvements and in parallel with them. So, the goal of 
seizure prevention (clinical and research) should be to abort 
the process of epileptogenesis in addition to short-term sei-
zure prevention, while not negatively affecting the process 
of post-TBI recovery. Multiple possible avenues need to be 
further investigated. 
At least theoretical grounds exist for the use of several 
existing and potential AEDs for seizure and PTE prevention 
in TBI. The possibilities include the use of anticonvulsants 
that exert activity against AMPA receptors, including lam-
otrigine and topiramate.109–112 In fact, in models of acute brain 
injury other than TBI, topiramate in the setting of therapeutic 
hypothermia has already been shown to be neuroprotective.113 
Further, talampanel and perampanel, two novel AEDs that 
are known AMPA antagonists, have also been shown to 
be antiepileptogenic; talampanel is also known to be neu-
roprotective.112 Since another AMPA-receptor antagonist, 
NS1209, with a mechanism of action similar to that of per-
ampanel (also a selective AMPA-receptor antagonist that 
decreases hyperexcitability by targeting glutamate activity 
at post-synaptic AMPA receptors110) has already been shown 
to be neuroprotective and effective in various animal models 
of epilepsy, including status epilepticus, we can probably 
assume all AEDs with this mechanism of action have simi-
lar properties.112 Other potential developments may include 
lacosamide because of its relative ease of use and the avail-
ability of intravenous and oral forms that are easily exchange-
able, and the fact that this AED has been shown to be 
potentially anti-epileptogenic in animal models of kindling.114 
Finally, ketamine, a N-methyl D-aspartate (NMDA) recep-
tor antagonist, has recently gained attention as a possible 
treatment of refractory status epilepticus; this drug is known 
to decrease or prevent NMDA-receptor up-regulation 
and thus decrease the possibility of neurotoxicity via 
glutamate cascade.115 This is especially important in view 
of a recent study that used CCI as a model of TBI to show 
that cortical excitability and glutamatergic signaling were 
altered following injury.5 The results of this study suggest 
that specific cortical neuronal microcircuits may initiate 
and facilitate the spread of epileptiform activity following 
TBI and increased glutamatergic signaling due to loss of 
GABAergic control, which may provide a mechanism by 
which TBI can give rise to PTE.
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